ClinVar Miner

Submissions for variant NM_004820.5(CYP7B1):c.1250G>A (p.Arg417His)

gnomAD frequency: 0.00006  dbSNP: rs121908611
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000206595 SCV000261512 pathogenic Spastic paraplegia 2023-12-02 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 417 of the CYP7B1 protein (p.Arg417His). This variant is present in population databases (rs121908611, gnomAD 0.01%). This missense change has been observed in individual(s) with autosomal recessive hereditary spastic paraplegia (PMID: 18252231, 19439420, 22384504). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 6103). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CYP7B1 protein function with a positive predictive value of 80%. This variant disrupts the p.Arg417 amino acid residue in CYP7B1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19439420, 21567895, 24658845). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000329074 SCV000330028 pathogenic not provided 2017-12-20 criteria provided, single submitter clinical testing The R417H variant in the CYP7B1 gene has been reported previously multiple times in the homozygous and compound heterozygous state in individuals with spastic paraplegia (Tsaousidou et al., 2008; Goizet et al., 2009; Marelli et al., 2017). Additional studies have also indicated that pathogenic variants involving R417 may impair catalytic function and indirectly affect ligand binding (Siam et al., 2012). The R417H variant is observed in 2/18838 (0.003%) alleles from individuals of Asian background, in large population cohorts and no individuals were reported to be homozygous (Lek et al., 2016). It is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. However, this substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Additionally, other missense variants at the same position (R417C and R417G) have been reported in the Human Gene Mutation Database in association with spastic paraplegia (Stenson et al., 2014). We interpret R417H as a pathogenic variant.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000006477 SCV000967608 likely pathogenic Hereditary spastic paraplegia 5A 2018-10-04 criteria provided, single submitter clinical testing The p.Arg417His variant in CYP7B1 has been reported in 6 individuals with spasti c paraplegia and two young children with oxysterol 7a-hydroxylase deficiency, an d segregated with spastic paraplegia in 10 affected relatives from 4 families (T saousidou 2008, Goizet 2009, Mizuochi 2011, Noreau 2012, Dai 2014). This variant has been identified in 2/18838 East Asian chromosomes by the Genome Aggregation Database (gnomAD, and is reported in ClinVar (Variation ID: 6103). Molecular modeling studies, computational prediction tool s, and conservation analysis suggest that the p.Arg417His variant may impact the protein, though this information is not predictive enough to determine pathogen icity (Siam 2012). In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classifi ed as likely pathogenic for autosomal recessive spastic paraplegia type 5. ACMG/ AMP criteria applied: PM3_Strong, PM2, PP1_Moderate, PP3.
Genome Diagnostics Laboratory, The Hospital for Sick Children RCV001847591 SCV002104547 pathogenic Hereditary spastic paraplegia 2020-10-15 criteria provided, single submitter clinical testing
Athena Diagnostics RCV000329074 SCV004229199 pathogenic not provided 2023-03-15 criteria provided, single submitter clinical testing The frequency of this variant in the general population is consistent with pathogenicity ( This variant segregates with spastic paraplegia in multiple families. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Computational tools predict that this variant is damaging.
PreventionGenetics, part of Exact Sciences RCV003894794 SCV004714941 pathogenic CYP7B1-related disorder 2024-02-27 criteria provided, single submitter clinical testing The CYP7B1 c.1250G>A variant is predicted to result in the amino acid substitution p.Arg417His. This variant was reported in the homozygous state in an individual with hereditary spastic paraplegia (Family 2, Tsaousidou et al 2008. PubMed ID: 18252231). This variant was also identified in the heterozygous state, and interpreted as pathogenic, in three individuals in a study utiziling exome sequencing for preconception carrier screening (Supplementary Table 1, Capalbo A et al 2019. PubMed ID: 31589614). Comparative modeling of CYP7B1 shows that the R417 amino acid resides in the meander region, which is the conserved PERF region, and suggests that any variant involving the R417 amino acid would be predicted to severely affect enzyme function (Siam A et al 2011. PubMed ID: 21541746). In addition, other variants impact the R417 amino acids have also been reported in individuals with hereditary spastic paraplegia (Goizet et al. 2009. PubMed ID: 19439420; Cao et al. 2011. PubMed ID: 21452256). This variant is reported in 0.010% of alleles in individuals of East Asian descent in gnomAD. Taken together, we interpret this variant as pathogenic.
OMIM RCV000006477 SCV000026660 pathogenic Hereditary spastic paraplegia 5A 2009-06-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.